Caplacizumab: 2019年fda批准的首个治疗成人获得性血栓性血小板减少性紫癜的药物

{"title":"Caplacizumab: 2019年fda批准的首个治疗成人获得性血栓性血小板减少性紫癜的药物","authors":"Feras Almarshad","doi":"10.37881/1.414","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"49 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Caplacizumab: First FDA-approved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura\",\"authors\":\"Feras Almarshad\",\"doi\":\"10.37881/1.414\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":383954,\"journal\":{\"name\":\"NeuroPharmac Journal\",\"volume\":\"49 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NeuroPharmac Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37881/1.414\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroPharmac Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37881/1.414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}